keyword
MENU ▼
Read by QxMD icon Read
search

Paclitaxel

keyword
https://www.readbyqxmd.com/read/29913480/dendrimer-paclitaxel-complexes-for-efficient-treatment-in-ovarian-cancer-study-on-ovcar-3-and-hek293t-cells
#1
Hua Yao, Jinqi Ma
The present paper investigates the enhancement of the therapeutic effect of Paclitaxel (a potent anticancer drug) by increasing its cellular uptake in the cancerous cells with subsequent reduction in its cytotoxic effects. To fulfill these goals the Paclitaxel (PTX)-Biotinylated PAMAM dendrimer complexes were prepared using biotinylation method. The primary parameter of Biotinylated PAMAM with a terminal HN2 group - the degree of biotinylation - was evaluated using HABA assay. The basic integrity of the complex was studied using DSC...
2018: Acta Biochimica Polonica
https://www.readbyqxmd.com/read/29912237/-paclitaxel-coated-balloons-for-in-stent-restenosis-treatment-long-term-clinical-results-and-predictors-of-recurrent-target-lesion-revascularization
#2
Irene Bossi, Margherita D'Anna, Valentina Vaccaro, Maria Paola Caria, Paola Colombo, Federico De Marco, Jacopo Oreglia, Giacomo Piccalò, Emanuela Piccaluga, Francesco Soriano, Fabrizio Oliva, Silvio Klugmann
BACKGROUND: The aim of this study was to report clinical outcomes in patients treated with paclitaxel-coated balloons (PCB) for in-stent restenosis (ISR) in both bare metal (BMS) and drug-eluting stent (DES). METHODS: Between May 2009 and December 2015, we treated 155 ISR in 140 patients. At recruitment, 35% of patients had diabetes. Among the lesions, 125 were first occurrence (55 within BMS and 70 within DES) and 30 recurrent; 24 ISR were multi-metal layered. Mean reference diameter was 2...
April 2018: Giornale Italiano di Cardiologia
https://www.readbyqxmd.com/read/29910834/lasting-pathologic-complete-response-to-chemotherapy-for-ovarian-cancer-after-receiving-antimalarials-for-dermatomyositis
#3
Isabella Cadena, Victoria P Werth, Pascale Levine, Annie Yang, Andrea Downey, John Curtin, Franco Muggia
Could hydroxychloroquine and quinacrine antimalarial therapy for dermatomyositis later attributed to a paraneoplasic manifestation of an ovarian cancer enhance its subsequent response to chemotherapy? Five months after being diagnosed with dermatomyositis, while somewhat improved with hydroxychloroquine, quinacrine and methotrexate, this 63-year-old woman presented with an advanced intra-abdominal epithelial ovarian cancer documented (but not resected) at laparotomy. Neoadjuvant carboplatin/paclitaxel resulted in remarkable improvement of symptoms, tumour markers and imaging findings leading to thorough cytoreductive surgery at completion of five cycles...
2018: Ecancermedicalscience
https://www.readbyqxmd.com/read/29910679/the-suppression-of-dusp5-expression-correlates-with-paclitaxel-resistance-and-poor-prognosis-in-basal-like-breast-cancer
#4
Tieju Liu, Huizhi Sun, Shiqi Liu, Zhao Yang, Linqi Li, Nan Yao, Siqi Cheng, Xueyi Dong, Xiaohui Liang, Chen Chen, Yi Wang, Xiulan Zhao
Basal-like breast cancer (BLBC) is resistant to endocrinotherapy and targeted therapy and new molecular therapies are needed for BLBC. In this study, we evaluated the role of DUSP1 and DUSP5, negative regulators of mitogen-activated protein kinase pathway, in the aggressiveness of BLBC. MDA-MB-231 cells were given paclitaxel (PTX) treatment and subsequently PTX resistant cell clones were established. Microarray analysis, real-time quantitative reverse transcription PCR (qRT-PCR), and online analysis of large cohorts of breast cancer patients were performed...
2018: International Journal of Medical Sciences
https://www.readbyqxmd.com/read/29910657/advances-in-the-systemic-treatment-of-triple-negative-breast-cancer
#5
REVIEW
J M Lebert, R Lester, E Powell, M Seal, J McCarthy
Triple-negative breast cancer constitutes a heterogeneous group of malignancies that are often aggressive and associated with a poor prognosis. Molecular characterization, while not a standard of care, can further subtype triple-negative breast cancer and provide insight into prognostication and behaviour. Optimal chemotherapy regimens have yet to be established; however, there have been advances in the systemic treatment of triple-negative breast cancer in the neoadjuvant, adjuvant, and metastatic settings...
June 2018: Current Oncology
https://www.readbyqxmd.com/read/29910647/antiangiogenic-therapies-in-non-small-cell-lung-cancer
#6
REVIEW
A Alshangiti, G Chandhoke, P M Ellis
Angiogenesis is frequent in non-small-cell lung cancer (nsclc) and is associated with more aggressive disease. Many clinical trials have evaluated the addition of antiangiogenic therapy to standard therapies for patients with nsclc. Bevacizumab, a monoclonal antibody directed against serum vascular endothelial growth factor, in combination with carboplatin-paclitaxel chemotherapy, has been shown to improve survival for patients with nsclc. However, bevacizumab-based therapy is not suitable for many nsclc patients, including those with squamous histology, poor performance status, brain metastases, and the presence of bleeding or thrombotic disorders...
June 2018: Current Oncology
https://www.readbyqxmd.com/read/29910636/performance-status-dynamics-during-treatment-with-nab-paclitaxel-plus-gemcitabine-versus-gemcitabine-alone-for-metastatic-pancreatic-cancer
#7
E Gabriela Chiorean, Daniel Von Hoff, Yin Wan, Sandra Margunato-Debay, Marc Botteman, David Goldstein
Objectives: This analysis examined changes in Karnofsky performance status (KPS) as a surrogate for patient's well-being during treatment with nab -paclitaxel plus gemcitabine vs gemcitabine alone as first-line therapy for metastatic pancreatic cancer (MPC) in the Phase III MPACT trial. Participants and methods: Descriptive analyses were performed for KPS at three time points (3 and 6 months after randomization and 1 month before disease progression) and for time to any KPS deterioration...
2018: Cancer Management and Research
https://www.readbyqxmd.com/read/29909520/lapatinib-in-combination-with-paclitaxel-plays-synergistic-antitumor-effects-on-esophageal-squamous-cancer
#8
Xiao-Fang Guo, Sai-Sai Li, Xiao-Fei Zhu, Qiao-Hua Dou, Duan Liu
PURPOSE: Paclitaxel-based chemoradiotherapy was proven to be efficacious in treating patients with advanced esophageal cancer. However, the toxicity and the development of resistance limited its anticancer efficiency. The present study was to evaluate the antitumor effects of lapatinib, a dual tyrosine inhibitor of both epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), combined with paclitaxel on the esophageal squamous cancer. METHODS: MTT assays were used to evaluate the effects of the combination of lapatinib and paclitaxel on the growth of esophageal squamous cancer cell lines (KYSE150, KYSE450, KYSE510 and TE-7)...
June 16, 2018: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29908205/real-time-and-in-vivo-pharmaceutical-and-environmental-studies-with-spidermass-instrument
#9
B Fatou, P Saudemont, M Duhamel, M Ziskind, C Focsa, M Salzet, I Fournier
Remote Infrared Matrix Assisted Laser Desorption Ionization (Remote IR MALDI) system (SpiderMass) with endogenous water as matrix allows to perform real-time DMPK in vivo. In this work, SpiderMass was used to analyze the impact on metabolite production or release of invalidated pro-protein PC1/3 macrophages by Short RNA (shRNA) versus scramble shRNA with Paclitaxel. Time course in vivo experiments were then performed on the inner and outer faces of patients' forearms or comedo treated with Melascreen (Ducray) containing ascorbyl glucoside...
June 13, 2018: Journal of Biotechnology
https://www.readbyqxmd.com/read/29906554/flim-reveals-alternative-ev-mediated-cellular-up-take-pathways-of-paclitaxel
#10
REVIEW
H Saari, E Lisitsyna, K Rautaniemi, T Rojalin, L Niemi, O Nivaro, T Laaksonen, M Yliperttula, E Vuorimaa-Laukkanen
In response to physiological and artificial stimuli, cells generate nano-scale extracellular vesicles (EVs) by encapsulating biomolecules in plasma membrane-derived phospholipid envelopes. These vesicles are released to bodily fluids, hence acting as powerful endogenous mediators in intercellular signaling. EVs provide a compelling alternative for biomarker discovery and targeted drug delivery, but their kinetics and dynamics while interacting with living cells are poorly understood. Here we introduce a novel method, fluorescence lifetime imaging microscopy (FLIM) to investigate these interaction attributes...
June 12, 2018: Journal of Controlled Release: Official Journal of the Controlled Release Society
https://www.readbyqxmd.com/read/29905759/biomarker-assessment-of-the-cbcsg006-trial-a-randomized-phase-iii-trial-of-cisplatin-plus-gemcitabine-compared-with-paclitaxel-plus-gemcitabine-as-first-line-therapy-for-patients-with-metastatic-triple-negative-breast-cancer
#11
J Zhang, Y Lin, X J Sun, B Y Wang, Z H Wang, J F Luo, L P Wang, S Zhang, J Cao, Z H Tao, J Wu, Z M Shao, W T Yang, X C Hu
Background: CBCSG006 trial reported the superior efficacy of cisplatin plus gemcitabine (GP) regimen than paclitaxel plus gemcitabine (GT) regimen as first-line treatment of metastatic triple-negative breast cancer (mTNBC). This study focused on the updated survival data and the explorations of potential biomarkers for efficacy. Patients and methods: Germ-line mutations of homologous recombination (HR) panel, BRCA1/2 included, were evaluated in 55.9% (132/236) patients...
June 14, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29905606/the-effect-of-the-histone-deacetylase-inhibitor-suberoylanilide-hydroxamic-acid-and-paclitaxel-treatment-on-full-thickness-wound-healing-in-mice
#12
Joseph H Marcotte, Deviney A Rattigan, Robin F Irons, Kevin W Cahill, Ping Zhang, Shaohua Chang, Kiavash R Koko, John P Gaughan, Jeffrey P Carpenter, Spencer A Brown, Tulin Budak-Alpdogan
INTRODUCTION: Neoadjuvant chemotherapy prior to lumpectomy or mastectomy for breast cancer challenges wound healing. Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, has been shown to work synergistically with paclitaxel in vitro and in preclinical studies. In addition, our laboratory has demonstrated that SAHA treatment decreases paclitaxel-associated stem cell toxicity, modulates inflammatory response, and promotes wound healing in injured fibroblast cells. Our goal was to determine if combined SAHA and paclitaxel treatment would improve wound healing in an in vivo full-thickness murine model, without altering antitumor effect...
June 13, 2018: Annals of Plastic Surgery
https://www.readbyqxmd.com/read/29903552/quality-adjusted-outcomes-stratified-by-response-in-patients-with-advanced-non-small-cell-lung-cancer-receiving-first-line-nab-paclitaxel-carboplatin-or-paclitaxel-carboplatin
#13
Vera Hirsh, Yin Wan, Fang-Ju Lin, Sandra Margunato-Debay, Teng Jin Ong, Marc Botteman, Corey Langer
BACKGROUND: First-line nab-paclitaxel/carboplatin was associated with a significantly improved overall response rate (primary endpoint) versus paclitaxel/carboplatin in a phase III trial of advanced non-small-cell lung cancer (NSCLC). We report the results of an analysis evaluating the correlation of response and the time to response with survival and quality-adjusted outcomes. PATIENTS AND METHODS: Using a landmark approach, progression-free survival (PFS), overall survival (OS), and quality-adjusted time without symptoms or toxicity (Q-TWiST) were compared between patients with a confirmed partial or complete response at or before 6 weeks (≤ 6-week responders) and those without (≤ 6-week nonresponders)...
May 7, 2018: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29903061/self-assembly-of-succinated-paclitaxel-into-supramolecular-hydrogel-for-local-cancer-chemotherapy
#14
Qianqian Song, Renshu Zhang, Lei Lei, Xingyi Li
In the present study, we reported the generation of a molecular hydrogel of succinated paclitaxel (PTX-SA) by a self-hydrolytic strategy for potential local cancer chemotherapy. Upon self-hydrolysis of the ester bond of PTX-SA in phosphate-buffered saline (pH = 7.4) for 24 h, a PTX-SA supramolecular hydrogel formed spontaneously with a minimal gelation concentration of 0.25 wt%. The formed PTX-SA supramolecular hydrogel displayed a filamentous nanostructure, the nanofibers of which were typically several micrometers in length with a diameter of 10-15 nm...
August 1, 2018: Journal of Biomedical Nanotechnology
https://www.readbyqxmd.com/read/29903054/ultrasound-triggered-drug-delivery-for-breast-tumor-therapy-through-irgd-targeted-paclitaxel-loaded-liposome-microbubble-complexes
#15
Jing Zhang, Song Wang, Zhiting Deng, Li Li, Guanghong Tan, Xin Liu, Hairong Zheng, Fei Yan
Liposome-microbubble complexes (LMC) have become a promising therapeutic carrier for ultrasound-triggered local drug release. However, it is still desirable for the released drugs to be delivered to tumors as effectively as possible. Here, we fabricated iRGD-targeted paclitaxel-loaded liposome-microbubble complexes (iRGD-PTX-LMC) and investigated the feasibility of enhancing the local drug delivery to breast tumors by using these complexes along with ultrasound irradiation. Our results showed that iRGD-modified PTX-loaded liposomes (iRGD-PTX-PL) were successfully conjugated to the surface of microbubbles (MBs) through biotin-avidin linkage...
August 1, 2018: Journal of Biomedical Nanotechnology
https://www.readbyqxmd.com/read/29902349/nab-paclitaxel-interrupt-cancer-stromal-interaction-through-cxcl10-mediated-il-6-down-regulation-in-vitro
#16
Rui Feng, Yuji Morine, Tetsuya Ikemoto, Satoru Imura, Syuichi Iwahashi, Yu Saito, Mitsuo Shimada
Cancer-associated fibroblasts (CAFs), which derived from cancer tissues stroma, interact with cancer cells and play an important role in cancer initiation, growth and metastasis. Nab-paclitaxel (nab-PTX) is the 130nm albumin binding paclitaxel and recommended for many kinds of cancer chemotherapy. It has been reported that nab-PTX stromal disrupting effect during pancreatic cancer treatment. The aim of this study is to illustrate the role of nab-PTX in cancer cells and CAFs interaction. The cancer cells (Mia paca2 and Panc-1) were co-cultured with CAFs or treat with CAFs conditioned medium, then their migration and invasion ability, epithelial-mesenchymal transition (EMT) related markers expression and CXCL10 expression and secretion were detected...
June 14, 2018: Cancer Science
https://www.readbyqxmd.com/read/29902299/association-of-t-cell-receptor-repertoire-use-with-response-to-combined-trastuzumab-lapatinib-treatment-of-her2-positive-breast-cancer-secondary-analysis-of-the-neoaltto-randomized-clinical-trial
#17
Ryan L Powles, David Redmond, Christos Sotiriou, Sherene Loi, Debora Fumagalli, Paolo Nuciforo, Nadia Harbeck, Evandro de Azambuja, Severine Sarp, Serena Di Cosimo, Jens Huober, Jose Baselga, Martine Piccart-Gebhart, Olivier Elemento, Lajos Pusztai, Christos Hatzis
Importance: Dual anti-HER2 blockade increased the rate of pathologic complete response (pCR) in the Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation (NeoALTTO) trial, and high immune gene expression was associated with pCR in all treatment arms. So far, no marker has been identified that is specifically associated with the benefit from dual HER2 blockade. Objective: To examine if use of the T-cell β chain variable genes adds to the potential association of immune gene signatures with response to dual HER2 blockade...
June 14, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29901731/characteristic-response-to-carboplatin-plus-paclitaxel-protein-bound-after-pembrolizumab
#18
Midori Nakamura, Keishi Oda, Fumihiro Tanaka, Kazuhiro Yatera
No abstract text is available yet for this article.
June 13, 2018: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29901596/multiple-gastrointestinal-metastases-of-squamous-cell-lung-cancer-a-case-report
#19
Xinyu Li, Songhe Li, Zhiming Ma, Shutao Zhao, Xudong Wang, Dacheng Wen
RATIONALE: Gastrointestinal multiple metastases of lung cancer are extremely rare. The majority of gastrointestinal metastasis cases are diagnosed at a late stage and the prognosis is extremely poor. This report describes the clinical characteristics and outcomes of a patient with gastrointestinal multiple metastases from squamous-cell lung cancer, with special emphasis on the diagnosis and treatment of metastatic lung cancer. PATIENT CONCERNS: A 61-year-old man who presented with progressive abdominal distention was admitted to our hospital...
June 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29901126/synergistic-apoptotic-effects-of-silibinin-in-enhancing-paclitaxel-toxicity-in-human-gastric-cancer-cell-lines
#20
Yuanxin Zhang, Yakun Ge, Xie Ping, Ming Yu, Dawei Lou, Wei Shi
Gastric cancer (GC) is the 3rd leading cause of tumor‑associated mortality worldwide. The efficacy of paclitaxel, a frequently used GC chemotherapeutic agent, is hindered due to drug resistance, dose‑induced toxicity and adverse side effects. Silibinin, an active compound of a widely consumed dietary supplement, milk thistle extract, has recently been demonstrated to have strong antitumor efficacy in a human GC cell model. Thus, to enhance the efficacy of GC treatment, the present study evaluated whether silibinin exerted a synergistic therapeutic effect with paclitaxel...
June 5, 2018: Molecular Medicine Reports
keyword
keyword
35091
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"